Philip Barnette
Overview
Explore the profile of Philip Barnette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pitchai F, Tanner E, Khetan N, Vasen G, Levrel C, Kumar A, et al.
Science
. 2024 Aug;
385(6709):eadn5866.
PMID: 39116226
Antiviral therapies with reduced frequencies of administration and high barriers to resistance remain a major goal. For HIV, theories have proposed that viral-deletion variants, which conditionally replicate with a basic...
2.
Kutzler M, Cusimano G, Joyner D, Konopka E, Muir R, Barnette P, et al.
Res Sq
. 2024 May;
PMID: 38746176
There is currently no prophylactic vaccine available for human immunodeficiency virus (HIV). Research efforts have resulted in improved immunogens that mimic the native envelope (Env) glycoprotein structure. Recently, a novel...
3.
Hioe C, Liu X, Banin A, Heindel D, Klingler J, Rao P, et al.
Front Immunol
. 2023 Nov;
14:1329069.
PMID: 38022586
[This corrects the article DOI: 10.3389/fimmu.2023.1271686.].
4.
Hioe C, Liu X, Banin A, Heindel D, Klingler J, Rao P, et al.
Front Immunol
. 2023 Oct;
14:1271686.
PMID: 37854587
Introduction: Neutralizing antibodies (Abs) are one of the immune components required to protect against viral infections. However, developing vaccines capable of eliciting neutralizing Abs effective against a broad array of...
5.
Goldberg B, Spencer D, Pandey S, Ordonez T, Barnette P, Yu Y, et al.
Proc Natl Acad Sci U S A
. 2023 May;
120(20):e2221247120.
PMID: 37155897
The first clinical efficacy trials of a broadly neutralizing antibody (bNAb) resulted in less benefit than expected and suggested that improvements are needed to prevent HIV infection. While considerable effort...
6.
Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
Rosenberg Y, Ordonez T, Khanwalkar U, Barnette P, Pandey S, Backes I, et al.
mBio
. 2023 Mar;
14(2):e0034123.
PMID: 36946726
Transplacental transfer of maternal antibodies provides the fetus and newborn with passive protection against infectious diseases. While the role of the highly conserved neonatal Fc receptor (FcRn) in transfer of...
7.
Weiss S, Itri V, Pan R, Jiang X, Luo C, Morris L, et al.
Nat Commun
. 2022 Feb;
13(1):903.
PMID: 35173151
V2p and V2i antibodies (Abs) that are specific for epitopes in the V1V2 region of the HIV gp120 envelope (Env) do not effectively neutralize HIV but mediate Fc-dependent anti-viral activities...
8.
Spencer D, Goldberg B, Pandey S, Ordonez T, Dufloo J, Barnette P, et al.
Nat Commun
. 2022 Feb;
13(1):662.
PMID: 35115533
Increasingly, antibodies are being used to treat and prevent viral infections. In the context of HIV, efficacy is primarily attributed to dose-dependent neutralization potency and to a lesser extent Fc-mediated...
9.
Sarkar S, Spencer D, Barnette P, Pandey S, Sutton W, Basu M, et al.
Front Immunol
. 2021 Nov;
12:757811.
PMID: 34745131
Induction of broadly neutralizing antibodies (bNAbs) is a major goal for HIV vaccine development. HIV envelope glycoprotein (Env)-specific bNAbs isolated from HIV-infected individuals exhibit substantial somatic hypermutation and correlate with...
10.
Klatt N, Broedlow C, Osborn J, Gustin A, Dross S, OConnor M, et al.
NPJ Vaccines
. 2021 Mar;
6(1):34.
PMID: 33707443
An effective vaccine to prevent HIV transmission has not yet been achieved. Modulation of the microbiome via probiotic therapy has been suggested to result in enhanced mucosal immunity. Here, we...